Keryx Biopharmaceuticals, Inc. is a biopharmaceutical company. It acquires, develops, and commercializes medically important pharmaceutical products for the treatment of cancer and renal disease. It develops KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase, or PI3K, pathway, and also affects a number of other key signal transduction pathways, including the JNK pathway, all of which are pathways associated with programmed cell death, growth, differentiation and survival. The company also develops Zerenex (ferric citrate), an oral, ferric iron-based compound that has the capacity to bind to phosphate in the gastrointestinal tract and form non-absorbable complexes. Keryx Biopharmaceuticals was founded in October 1998 and is headquartered in New York, NY.
Keryx Biopharmaceuticals, Inc.
750 Lexington Avenue 20th floor
New York, NY 10022
SIC Code: 8731